Safety of a Novel Weight Loss Combination Product Containing Orlistat and Acarbose.

ABSTRACT: The safety of a novel modified-release oral capsule with orlistat and acarbose (MR-OA) was investigated in 67 obese middle-aged White men with a body mass index of 32 to 40 kg/m² or 30 to 32 kg/m² plus waist circumference >102 cm. The purpose of this investigation was to compare MR-OA with the existing conventional orlistat regarding systemic safety defined as plasma orlistat concentration at the end of the treatment period of 14 days. Participants took the MR-OA fixed-dose combination formulation 3 times a day together with a major meal. Three different doses of MR-OA were evaluated-60/20, 90/30, and 120/40 (mg orlistat/mg acarbose)-as well as 1 reference group who received the conventional orlistat, Xenical, with 120 mg of orlistat. Blood plasma was sampled on days

SUBMITTER: Gruden S 

PROVIDER: S-EPMC8518499 | biostudies-literature | 2021 Oct

REPOSITORIES: biostudies-literature